US2017202791A1PendingUtilityA1

N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases

56
Assignee: EMERAMED LTDPriority: May 30, 2014Filed: May 29, 2015Published: Jul 20, 2017
Est. expiryMay 30, 2034(~7.8 yrs left)· nominal 20-yr term from priority
Inventors:Boyd E. HaleyRagnar Axel Theodor Klingberg
A61K 31/166A61P 25/28A61K 45/06A61K 31/428A61K 31/198A61K 31/13A61K 31/4745A61K 31/165Y02A50/30
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in the therapeutic treatment of a neurodegenerative disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and/or amyotrophic lateral sclerosis.

Claims

exact text as granted — not AI-modified
1 - 2 . (canceled) 
     
     
         3 . A method of treatment of a neurodegenerative disorder, which method comprises the administration of N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, to a patient in need of such treatment. 
     
     
         4 . A method of relieving one or more symptom of a neurodegenerative disorder in a patient suffering therefrom, which method comprise administering N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, to such a patient. 
     
     
         5 . The method as claimed in  claim 3 , wherein the neurodegenerative disorder is Alzheimer's disease. 
     
     
         6 . The method as claimed in  claim 5 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from a cholinesterase inhibitor or a NMDA receptor antagonist. 
     
     
         7 . The method as claimed in  claim 3 , wherein the neurodegenerative disorder is Parkinson's disease. 
     
     
         8 . The method as claimed in  claim 7 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from levodopa (optionally along with a dopamine decarboxylase inhibitor), a dopamine agonist, a MAO-B inhibitor, amantadine or an anticholinergic compound. 
     
     
         9 . The method as claimed in  claim 3 , wherein the neurodegenerative disorder is Huntington's disease. 
     
     
         10 . The method as claimed in  claim 9 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from tetrabenazine, amantadine or remacemide. 
     
     
         11 . The method as claimed in  claim 3 , wherein the neurodegenerative disorder is amyotrophic lateral sclerosis. 
     
     
         12 . The method as claimed in  claim 11 , wherein the patient is also receiving therapy which comprises administration of riluzole. 
     
     
         13 . The method as claimed in  claim 4 , wherein the neurodegenerative disorder is Alzheimer's disease. 
     
     
         14 . The method as claimed in  claim 13 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from a cholinesterase inhibitor or a NMDA receptor antagonist. 
     
     
         15 . The method as claimed in  claim 4 , wherein the neurodegenerative disorder is Parkinson's disease. 
     
     
         16 . The method as claimed in  claim 15 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from levodopa (optionally along with a dopamine decarboxylase inhibitor), a dopamine agonist, a MAO-B inhibitor, amantadine or an anticholinergic compound. 
     
     
         17 . The method as claimed in  claim 4 , wherein the neurodegenerative disorder is Huntington's disease. 
     
     
         18 . The method as claimed in  claim 17 , wherein the patient is also receiving therapy which comprises administration of an active ingredient selected from tetrabenazine, amantadine or remacemide. 
     
     
         19 . The method as claimed in  claim 4 , wherein the neurodegenerative disorder is amyotrophic lateral sclerosis. 
     
     
         20 . The method as claimed in  claim 19 , wherein the patient is also receiving therapy which comprises administration of riluzole.

Join the waitlist — get patent alerts

Track US2017202791A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.